Great Point Partners’s Akero Therapeutics AKRO Stock Holding History

Great Point Partners’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-103,848	Closed	-$4.93M	–	32
2025 Q3	$4.93M	Hold	103,848	–	–	2.03%	18
2025 Q2	$5.54M	Buy	+103,848	New	+$4.72M	3.6%	11
2023 Q4	–	Sell	-198,500	Closed	-$10M	–	38
2023 Q3	$10M	Buy	+198,500	New	+$9.24M	1.83%	26

Other funds holding AKRO

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Great Point Partners's AKRO Position: Q4 2025 in Review

Great Point Partners sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 103,848 shares — an estimated $4.93M sold.

Great Point Partners first reported a position in AKRO in Q3 2023 and held it in 3 quarters. The position peaked at $10M in Q3 2023. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

Great Point Partners reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
Great Point Partners sold 103,848 Akero Therapeutics shares in Q4 2025, an estimated $4.93M.
Great Point Partners first reported a position in Akero Therapeutics in Q3 2023 and held it in 3 quarters.
Great Point Partners's Akero Therapeutics position peaked at $10M in Q3 2023.
2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Great Point Partners's 13F filing for Q4 2025, filed 17 Feb 2026.